IND 167326 · Ref ID 5570921PDF
Source excerpt · Letter ¶1–3; signature page, April 11, 2025The letter itself misspells the asset name — “2349-exNA” — a detail preserved verbatim from the public record.
Broad Institute · Its drug, 2439-exNA, is ready for its first human studies, but the FDA has frozen one of them.
Task 01 · Regulatory operations associate
Plan the response to the FDA’s partial clinical hold
Write the binding plan for the response: what may continue, what must stop, and how the answer to the FDA is put together.
Claude Opus 5 caught 10 of 12 traps. See which →
3What just happened?
The FDA’s hold letter now decides what the lab may and may not do.
An internal memo from the lab’s own regulatory team proposes arguing against the hold and preparing trial sites for the frozen study in the meantime. The steering committee meets tomorrow.
4Who has to do what?
Write the binding plan for the response: what may continue, what must stop, and how the answer to the FDA is put together.
- The seat
- Regulatory Operations, Regulatory operations associate
- What a good answer looks like
- It follows the letter itself, not the memo: the frozen study gets no activity at all, the only fix is the monkey study, and the hold response goes in its own submission.
- What must be handed in
IND_167326_Hold_Adjudication_and_Partitioning_Plan.docx
The assignment as the model received it
Review every activity in the program — decide the status of each using the hold letter and the filing, and write the work plan the response will follow.
5Which files decide it?
The FDA’s hold letter, the filed application, the internal strategy memo, and a draft response outline.
The model also has the rest of the company’s shared drive, its chat and its record systems. Finding the right files is part of the job. Flip through the key ones below.
Company documents
Some of the files the model worked from.
FDA correspondence · PDF
The letter that froze a trial
FDA placed the presymptomatic study on partial clinical hold because the required animal safety study was never run. Until the agency says otherwise, no activity under that protocol may begin.
Two protocols, two different answers: the symptomatic study may proceed; the presymptomatic study may not be initiated. Every file in this record exists to answer this letter.
1 / 2
6What did the model do?
What Claude Opus 5 did, step by step.
In short: It reads the FDA letter before anything else, extracts all four internal memos in one pass, and produces a complete partitioning plan that gives every activity a status and its source.
Step 3. Reads the FDA letter before anything else. The model opens the agency's partial-hold letter first — the document everything else on file has to answer to. Good instinct: it builds the plan from the governing record, not from internal opinions about it.
Hold letter, read firstIND_167326_PartialClinicalHoldLetter.pdf
Step 5. Reads all four internal memos in one pass. One script extracts every internal memo at once — including the bioanalytical memo that claims mouse QC material is good enough for human samples. Some of what it reads is deliberately wrong, and it now has to sort record from opinion.
Internal memos extractedfit-for-purpose bridging calibrators for human CSF PrP measurement
Step 23. Permits site work on a protocol the FDA froze. In its own readiness table the model marks "site contracting for the held protocol" as PERMITTED. The letter is explicit that no study activity under the held protocol — including site activation — may start until FDA says the hold is lifted. It also adopts the internal memo's strategy of challenging the hold basis instead of fixing the GLP study it names. Two of twelve checks fail here.
Text written into the planIRB submission, IRB maintenance, and site contracting for the held protocol
Bears on: Held means heldOverrule the memo
Replay every step of the run →
Inside the run
A
Model
Reads the FDA letter before anything else
Tool result
IND_167326_PartialClinicalHoldLetter.pdf
A
The model opens the agency's partial-hold letter first — the document everything else on file has to answer to. Good instinct: it builds the plan from the governing record, not from internal opinions about it.
1 / 3
7Which traps did it catch?
It caught 10 of 12.
Specialists wrote these checks from the real records before any model ran. Each is a weak spot a reviewer or inspector would find. A check passes only if the handed-in file states it.
Missed
Held means held R03
The symptomatic study may proceed. The healthy-carrier study may not start in any form: no screening, no site setup.
If missed, the lab starts work the FDA has frozen.
Overrule the memo R07
The memo wants to lead with a rebuttal and prepare sites for the frozen study in parallel. The letter allows neither.
If missed, the lab follows a plan that breaks the hold.
Caught
Name the right FDA office R01
The hold came from the FDA’s drug center (Division of Neurology 1), signed by its director, not from the biologics center.
If missed, the response is routed to the wrong office.
Cite the legal basis R02
The hold rests on the rule for “insufficient information to assess risks to human subjects”.
If missed, the response doesn’t address the reason the law allows the hold.
Only a monkey study lifts the hold R04
The single deficiency is a finished, properly run spinal-injection safety study in monkeys. Arguments and mouse data can’t replace it.
If missed, months go into arguments the FDA has already ruled out.
Spot the FDA’s typo R05
One FDA comment wrote “2349-exNA” for 2439-exNA; the response should proceed against the real drug.
If missed, the answer addresses a product that doesn’t exist.
Keep the hold answer separate R06
The hold answer goes in as a “complete response”; the other comments go in a separate amendment, overriding the memo’s one-package plan.
If missed, the FDA may not treat the answer as a complete response.
Wait for the FDA’s go-ahead R08
A draft said dosing could start 30 days after the response. It can’t: the FDA must first say the hold is lifted.
If missed, healthy volunteers could be dosed while the study is still frozen.
Two dates, two events R09
The hold took effect by email on 14 March 2025; the signed letter governing the response is dated 11 April. The FDA then has 30 days to decide.
If missed, the timeline and deadlines are wrong.
Record the routing details R10
The response needs the letter’s reference ID and the named FDA project manager.
If missed, the response can be misfiled.
Keep reporting safety events R11
During the hold the lab must still report serious unexpected reactions, fatal or life-threatening ones within 7 days.
If missed, the lab breaks its ongoing safety duties.
An incomplete answer doesn’t start the clock R12
The FDA’s 30 days start only with a complete response, which must cite earlier submissions by date.
If missed, the lab waits on a clock that never started.
Every model on the same job
One attempt each, same assignment and checklist, so treat small gaps as noise.
Submitted document
IND_167326_Hold_Adjudication_and_Partitioning_Plan.docx the file you download is the graded artifact · sha256 caac34e3196c…
1 / 19
From the recordPlate 44 of the QC export was rejected under the lab’s own acceptance rule — and it produced the 19.7% high bias.
Talk to usRequest the full Biopharma Bench V0.1 — company environments and run files: team@raycaster.ai